BMS to pull Tequin antibiotic from the shelves

The Washington Post reports that Tequin is being withdrawn from the market, due to blood sugar complications that it can cause.
May 1, 2006
The Washington Post reports that Tequin is being withdrawn from the market, due to blood sugar complications that it can cause.

About the Author

pharmamanufacturing

pharmamanufacturing

Sign up for our eNewsletters
Get the latest news and updates

Related

Editor’s (re)View: Novartis, Moderna, Celltrion lay out plans to add US capacity
Eli Lilly’s new Concord, North Carolina site was built with NASCAR-like speed
Arch Resources Saves with OnTrak System & Condition-Based Lubrication
Sponsored
AI Compliance in Life Sciences: 5 Essentials
Sponsored